LogoBiotechNW
The life science and biotech PR distribution service

New Sartorius Stedim BioOutsource Microsite Goes Live

sarto-stedim-bio logo

Cellca’s Cell Line and Upstream Process Development Services Now Integrated

Glasgow, UK, June 14, 2016 / B3C newswire / -- Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry announced that its subsidiary BioOutsource launched an updated website to spotlight Sartorius Stedim Cellca’s cell line and upstream process development services for the biopharmaceutical industry. The new microsite features insights into the technology and development services of Cellca most recently acquired by SSB. The availability of both subsidiaries’ unique range of integrated services will support biopharma companies to rapidly and cost-effectively develop their biologics and biosimilars.

The new microsite divides into four easy-to-navigate sections that explain Cellca’s unique CHO Expression Platform which comprises of Expression Vector, Host Cell Line, CHO Media System and Upstream Process Design. This structure gives a simple overview of the technical details and time-saving benefits of this robust, scalable expression platform for individual applications.  

Cellca’s cell line and upstream process development services complement BioOutsource’s broad range of bioanalytical and biosafety testing, as well as pre-qualified biosimilar assays. As a result, scientists and potential customers can source all their needs for developing biologics and biosimilars from one trusted supplier. Additionally, as both Cellca and BioOutsource have been part of Sartorius Stedim Biotech since 2015, biopharma firms that need to commercialize their biologics will not only benefit from this niche expertise, but can also access Sartorius Stedim Biotech’s extensive global upstream process development capabilities to accelerate the development timeline of their biologics and biosimilars.   

Gerry MacKay, Managing Director of Sartorius Stedim BioOutsource, commented: “We’re pleased to be launching our new microsite because it signals the availability of our unique integrated services. Developers of biologics and biosimilars can now go to our site to find out how to access a fully integrated pathway from cell line development and data characterization through to upstream process development. They can also discover how these services will support them to comply with regulatory standards for timely, cost-effective development of their biosimilars.”

To find out about Cellca’s cell line and upstream process development services, scientists should click this link to the new microsite: www.biooutsource.com/cell-line-and-upstream-process-development/


A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a global reach. The company employs approx. 4,200 people, and in 2015 earned sales revenue of 884.3 million euros.

A profile of Sartorius Stedim BioOutsource Ltd.
Now part of Sartorius Stedim Biotech Group, BioOutsource provides contract testing services to the biopharmaceutical industry. Our core offering includes a comprehensive range of services to support the testing of biologics, vaccines & biosimilars throughout their development. We possess an unparalleled combination of commercial, regulatory and technical knowledge that enables us to truly stand out as the industry’s increasingly preferred testing partner. We understand the importance of our service to support our client’s critical testing requirements and as a result, continually strive to provide a world class service globally. 

A profile of Sartorius Stedim Cellca GmbH
Cellca, founded in 2005 and part of the Sartorius Stedim Biotech Group, is a leading provider of cell line and upstream process development services for large-scale protein production of biopharmaceuticals in mammalian cells. Based on our in-depth expertise, know-how, and intellectual property, we have established the unique CHO Expression Platform technology, which is designed to deliver high yielding, stable CHO cell lines and robust, scalable fed-batch processes for the pharma and biotech industries. Our customers and partners benefit from a reduction of their cost of goods, the reduction of development risks, and a faster time-to-clinic.

Headquartered in Laupheim, Germany, Cellca currently has a staff of 50 employees and generated sales revenue of approximately €6 million in 2014. 


Contacts

Gemma Fulton
Marketing Manager
Sartorius Stedim BioOutsource Ltd,
Glasgow, United Kingdom
Phone +44(0)141.946.4222
Fax +44(0)141.946.4552
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.biooutsource.com

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok